Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape

PLoS Med. 2019 Mar 22;16(3):e1002767. doi: 10.1371/journal.pmed.1002767. eCollection 2019 Mar.

¹ School of Medicine, UCSF Center for TB, University of California San Francisco, San Francisco, California, United States of America.
² Harvard Medical School, Boston, Massachusetts, United States of America.
³ School of Public Health, University of Minnesota, Minneapolis, Minnesota, United States of America.
⁴ Unité Mixte Internationale TransVIHMI (UMI 233 IRD, U1175 INSERM, Université de Montpellier), Institut de Recherche pour le Développement Montpellier, Montpellier, France.
⁵ Medical Research Council Clinical Trials Unit at University College London, London, United Kingdom.

Abstract

In a Collection Review, Patrick Phillips and colleagues discuss developments in clinical trial design for the evaluation of TB therapeutics.